Amyloid β protein (Aβ) is the main component of neuritic plaques in Alzheimer's disease
(AD), and its accumulation has been considered as the molecular driver of Alzheimer's …

Astrocytes and microglia are central players in a myriad of processes in the healthy and
diseased brain, ranging from metabolism to immunity. The crosstalk between these two cell …

Alzheimer's disease (AD) is heterogenous at the molecular level. Understanding this
heterogeneity is critical for AD drug development. Here we define AD molecular subtypes …

Brain exposure of systemically administered biotherapeutics is highly restricted by the blood-
brain barrier (BBB). Here, we report the engineering and characterization of a BBB transport …

Antisense oligonucleotides (ASOs) are promising therapeutics for treating various
neurological disorders. However, ASOs are unable to readily cross the mammalian blood …

Synapse dysfunction and loss are hallmarks of neurodegenerative diseases that correlate
with cognitive decline. However, the mechanisms and therapeutic strategies to prevent or …

Human genetics and preclinical studies have identified key contributions of TREM2 to
several neurodegenerative conditions, inspiring efforts to modulate TREM2 therapeutically …

Alzheimer disease (AD) is the most common neurodegenerative disease, and with no
efficient curative treatment available, its medical, social, and economic burdens are …

Triggering receptor expressed on myeloid cells 2 (Trem2) is a myeloid cell-specific gene
expressed in brain microglia, with variants that are associated with neurodegenerative …

Recent discoveries of rare variants of human APOE may shed light on novel therapeutic
strategies for Alzheimer's disease (AD). Here, we highlight the newly identified protective …